BRAFV600E与TERT启动子突变共存对甲状腺乳头状癌不良临床结局的影响:一项Meta分析
该Meta分析纳入13项研究共4347例甲状腺乳头状癌(PTC)患者,其中283例(中位数8.3%)存在BRAFV600E与TERT启动子突变共存。共存突变与高危临床病理特征及复发风险的相关性远强于任一单突变,且PTC相关死亡率显著高于仅BRAFV600E突变者。作者认为联合检测两种突变有助于PTC风险分层。
要点
- 共存突变与晚期TNM分期、腺外侵犯、淋巴结转移及远处转移的风险均高于任一单突变。
- 共存突变者复发风险最高(vs 无突变 HR=6.60),BRAFV600E或TERT单突变与无突变相比未达统计学显著。
- 共存突变者PTC相关死亡率显著高于仅BRAFV600E突变者(HR=20.07)。
核心结论
- BRAFV600E与TERT启动子突变共存对PTC临床结局有协同效应,而各突变单独存在时效应有限。
- 作者认为联合检测BRAFV600E与TERT启动子突变有助于PTC的风险分层评估。
研究设计与样本
- Meta分析,检索PubMed和Embase数据库(建库至2016年9月),纳入分析BRAFV600E与TERT启动子突变和临床病理特征、复发或PTC相关死亡相关性的研究。
- 共纳入13项合格研究,包含4347例PTC患者,其中283例(中位数8.3%)存在BRAFV600E与TERT启动子突变共存。
主要发现
- 共存突变与晚期TNM分期的关联:vs BRAFV600E OR=4.19(CI 3.07-5.71);vs TERT OR=4.66(CI 2.67-8.13)。
- 共存突变与腺外侵犯的关联:vs BRAFV600E OR=3.1(CI 2.2-4.37);vs TERT OR=5.66(CI 3.02-10.6)。
- 共存突变与淋巴结转移的关联:vs BRAFV600E OR=1.59(CI 1.16-2.17);vs TERT OR=2.03(CI 1.22-3.38)。
- 共存突变与远处转移的关联:vs BRAFV600E OR=11.76(CI 5.63-24.58)。
- 复发风险:共存突变 vs 无突变 HR=6.60(CI 3.82-11.40);BRAFV600E vs 无突变 HR=1.31(CI 0.49-3.46);TERT vs 无突变 HR=3.38(CI 0.85-13.35);共存突变者PTC相关死亡率显著高于仅BRAFV600E突变者(HR=20.07,CI 8.37-48.09)。
关键数值与推荐
- 共存突变与晚期TNM分期关联的OR=4.19(vs BRAFV600E,CI 3.07-5.71)和OR=4.66(vs TERT,CI 2.67-8.13)。
- 共存突变与腺外侵犯关联的OR=3.1(vs BRAFV600E,CI 2.2-4.37)和OR=5.66(vs TERT,CI 3.02-10.6)。
- 共存突变与淋巴结转移关联的OR=1.59(vs BRAFV600E,CI 1.16-2.17)和OR=2.03(vs TERT,CI 1.22-3.38)。
- 共存突变与远处转移关联的OR=11.76(vs BRAFV600E,CI 5.63-24.58)。
- 复发风险HR=6.60(共存突变 vs 无突变,CI 3.82-11.40);PTC相关死亡HR=20.07(共存突变 vs 仅BRAFV600E突变,CI 8.37-48.09)。
临床怎么用
- 作者认为,联合检测BRAFV600E与TERT启动子突变有助于评估PTC的风险分层。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The presence of a telomerase reverse transcriptase (TERT) promoter mutation has been suggested as a potential prognostic marker for thyroid cancer, and a synergistic association with the BRAFV600E mutation has been demonstrated. The aim of this study was to verify the role of this genetic duet in papillary thyroid cancer (PTC). METHODS: Studies of the association of BRAFV600E and TERT promoter mutations with clinicopathologic features, recurrence, or PTC-related mortality were included from PubMed and Embase databases (inception to September 2016). RESULTS: Thirteen eligible studies incorporating 4347 patients with PTC were included, and 283 (median 8.3%) of these patients had coexistent BRAFV600E and TERT promoter mutations. The coexistence of the two mutations was far more strongly associated with high-risk clinicopathologic features than either mutation alone was, including advanced TNM stage (vs. BRAFV600E: odds ratio [OR] = 4.19 [confidence interval (CI) 3.07-5.71]; vs. TERT: OR = 4.66 [CI 2.67-8.13]), extrathyroidal extension (vs. BRAFV600E: OR = 3.1 [CI 2.2-4.37]; vs. TERT: OR = 5.66 [CI 3.02-10.6]), lymph node metastasis (vs. BRAFV600E: OR = 1.59 [CI 1.16-2.17]; vs. TERT: OR = 2.03 [CI 1.22-3.38]), and distant metastasis (vs. BRAFV600E: OR = 11.76 [CI 5.63-24.58]). The coexistence of the mutations showed the highest risk of recurrence (coexistence vs. no mutations: hazard ratio [HR] = 6.60 [CI 3.82-11.40]; BRAFV600E vs. no mutations: HR = 1.31 [CI 0.49-3.46]; TERT vs. no mutations: HR = 3.38 [CI 0.85-13.35]). Moreover, PTC-related mortality was significantly higher with coexistent mutations than in the presence of BRAFV600E alone (HR = 20.07 [CI 8.37-48.09]). CONCLUSIONS: Coexistent BRAFV600E and TERT promoter mutations have a synergistic effect on clinical outcomes in PTC, whereas each mutation alone has a modest effect. Therefore, molecular testing of BRAFV600E and TERT promoter mutations together is useful in assessing risk stratification of PTC.
引用
- Moon S, Song YS, Kim YA, et al. Effects of Coexistent BRAFV600E and TERT Promoter Mutations on Poor Clinical Outcomes in Papillary Thyroid Cancer: A Meta-Analysis. Thyroid. 2017. PMID: 28181854. doi:10.1089/thy.2016.0350
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。